# Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Chimp Adenovirus Vaccines Expressing Clade C gp140 & CH505TF gp120 Protein Boost in HIV-uninfected Adult.

> **NCT05182125** · PHASE1 · COMPLETED · sponsor: **HIV Vaccine Trials Network** · enrollment: 34 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** AdC6-HIVgp140
- **BIOLOGICAL:** AdC7-HIVgp140
- **BIOLOGICAL:** CH505TF gp120
- **BIOLOGICAL:** GLA-SE (glucopyranosyl lipid A - stable emulsion; [labeled as AP 10-201])
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05182125
- **Lead sponsor:** HIV Vaccine Trials Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-11-25
- **Primary completion:** 2023-08-21
- **Final completion:** 2025-05-14
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2025-12-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05182125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05182125, "Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Chimp Adenovirus Vaccines Expressing Clade C gp140 & CH505TF gp120 Protein Boost in HIV-uninfected Adult.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05182125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*